LSV Asset Management
RIGL icon

LSV Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

LSV Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.3M Buy
601,507
+57,225
+11% +$1.92M 0.04% 337
2025
Q4 		$23.3M Buy
544,282
+433,382
+391% +$16.3M 0.05% 305
2025
Q3 		$3.14M Buy
110,900
+15,200
+16% +$455K 0.01% 525
2025
Q2 		$1.79M Buy
+95,700
New +$1.81M ﹤0.01% 567

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LSV Asset Management's RIGL Position: Q1 2026 in Review

LSV Asset Management increased its Rigel Pharmaceuticals (RIGL) stake by 11% in Q1 2026, buying an estimated $1.92M and bringing the position to 601,507 shares worth $16.3M. The position accounts for 0.04% of the portfolio, ranked #337.

LSV Asset Management first reported a position in RIGL in Q2 2025 and has held it in 4 quarters since. The position peaked at $23.3M in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • LSV Asset Management held 601,507 shares of Rigel Pharmaceuticals worth $16.3M as of Q1 2026.
  • LSV Asset Management bought 57,225 Rigel Pharmaceuticals shares in Q1 2026, an estimated $1.92M.
  • Rigel Pharmaceuticals made up 0.04% of LSV Asset Management's portfolio in Q1 2026, its #337 holding.
  • LSV Asset Management first reported a position in Rigel Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • LSV Asset Management's Rigel Pharmaceuticals position peaked at $23.3M in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on LSV Asset Management's 13F filing for Q1 2026, filed 11 May 2026.